Developer docs
API playgroundTry for free, no card

Search company profiles

Flare Therapeutics

Full company profile

uuid0000ls7

Namestring
Flare Therapeutics
Legal namestring
Flare Therapeutics Inc.
Websiteurl
flaretx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Flare's business model is currently pre-revenue and built on three pillars: (1) equity-financed internal drug development, with $82M raised in Series A (May 2021) and $123M in Series B (March 2023), totaling $205M in venture capital from investors including Third Rock Ventures, GordonMD Global Investments LP, Pfizer Ventures, Eli Lilly, Novartis, and Memorial Sloan Kettering Cancer Center; (2) strategic discovery and licensing collaborations, most notably the November 2024 Roche agreement providing $70M upfront plus potential milestones exceeding $1.8B and royalties, with Flare retaining ownership of its existing pipeline; and (3) clinical-trial collaborations, including a Merck supply agreement to evaluate FX-909 with KEYTRUDA. Future revenue is expected to come from drug commercialization (FX-909 targeting ~14,000 US cases of PPARG-high advanced urothelial cancer per year, within an 83,000+ US annual bladder cancer incidence), licensing royalties, and milestone payments. Distribution is conducted through approximately 12-15 US clinical trial sites under standard Phase 1B protocols. Leadership includes CEO Douglas Manion (appointed April 2024, formerly of Arena, Aclaris, BMS, GSK), CSO/Co-founder Robert Sims (ex-Constellation Pharmaceuticals), President/CFO Daphne Karydas, and CDO Michaela Bowden.

Short descriptiontext

Flare Therapeutics is a clinical-stage biotechnology company developing precision oncology drugs by targeting transcription factors via its proprietary switch-site drug discovery platform. Its lead candidate FX-909 is in Phase 1B for biomarker-defined advanced urothelial cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, transcription factor drug discovery, small molecule cancer drugs, clinical-stage biotechnology, urothelial cancer treatment
Industry2 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Oncology Therapeutics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Commercialization
TypeLicensing Royalties
Description

Clinical-stage biotech with lead program FX-909 in Phase 1B. Revenue will come from drug sales upon regulatory approval. Partnered with Roche for discovery collaboration receiving $70M upfront with potential milestones exceeding $1.8B and royalties.

flaretx.com
2Partnership and Collaboration Revenue
TypeLicensing Royalties
Description

Strategic discovery collaboration with Roche worth up to $1.8B+ in milestones plus royalties. Retains co-funding option for one target for increased US royalties.

flaretx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Flare Therapeutics is a clinical-stage biotechnology company developing precision oncology small-molecule drugs that target transcription factors using its proprietary "switch-site" drug discovery platform. Its lead asset FX-909 is an orally bioavailable PPARG inhibitor currently in Phase 1B clinical trials for biomarker-defined advanced urothelial cancer, and its second program FX-111 is a heterobifunctional degrader of ARON in IND-enabling studies for metastatic castration-resistant prostate cancer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Tumor regressions in 18 of 25 biomarker-defined patients (72%) including 5 confirmed partial responses and 1 complete response in Phase 1A study
+3 more records
Product overview1 text field

Flare Therapeutics is a clinical-stage biotechnology company with a proprietary switch-site drug discovery platform focused on targeting transcription factors for precision oncology. The platform has identified more than 150 switch sites across transcription factor families. The company has two lead drug candidates: FX-909 (Phase 1B for urothelial cancer) and FX-111 (IND-enabling stage for prostate cancer), along with a discovery-stage portfolio targeting transcription factors in oncology and other therapeutic areas.

Product and service2 records
1FX-909
CategoryDrug Candidate
Description

First-in-class orally bioavailable small molecule inhibitor of PPARG (peroxisome proliferator-activated receptor gamma), a master regulator of the luminal lineage. Currently in Phase 1B clinical trial for locally advanced or metastatic urothelial cancer in biomarker-defined PPARG-high patient population.

2FX-111
CategoryDrug Candidate
Description

First-in-class heterobifunctional degrader of ARON (transcriptionally active, hormone-bound conformation of the androgen receptor). Currently in IND-enabling studies for treatment of metastatic castration-resistant prostate cancer (mCRPC).

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-21
Description

Clinical trial collaboration and supply agreement to evaluate FX-909 in combination with KEYTRUDA (pembrolizumab) in new cohort of ongoing Phase 1 trial in metastatic urothelial cancer. Addresses potential to combine PPARG inhibition with anti-PD1 to overcome immune resistance.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-12
Description

Strategic discovery collaboration leveraging Flare's proteomic and mass spectrometry platform to discover novel small molecule drugs targeting previously undrugged transcription factor targets in oncology. Flare receives $70M upfront and potential milestones exceeding $1.8B plus royalties. Flare retains co-funding option for one target for increased US royalties and retains ownership of existing pipeline.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-10-04
Description

Partnership to develop AI-based model that identifies luminal subtype urothelial cancer characterized by high PPARG expression using H&E-stained slides. Model achieved AUROC ≥95% accuracy across test, validation and independent datasets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-13
Description

Multi-year strategic preferred portfolio partnership providing comprehensive molecular profiling (whole exome and whole transcriptome sequencing) for patients in Flare's clinical trials. Leverages Caris' clinico-genomic database and AI/ML capabilities for biomarker-driven patient selection. Caris receives first option to develop companion diagnostic for any drug candidate from collaboration.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical-stage precision oncology company developing inhibitors of difficult-to-drug oncogenic drivers (RAS, SHP2) with biomarker-defined patient strategies similar to Flare's PPARG-high urothelial approach.

TypeDirect peer
Description

Clinical-stage biotech using targeted protein degradation (Pegasus platform) to address transcription factors and other previously undruggable targets in oncology and immunology, with comparable platform-based pipeline strategy.

TypeDirect peer
Description

Clinical-stage biotech developing small molecule drugs against transcription factors and chromatin regulatory complexes for oncology, using a related 'gene traffic control' platform approach. Directly comparable as a transcription factor-targeting peer in precision oncology.

TypeDirect peer
Description

Clinical-stage biotech developing small molecule degraders (TORPEDO platform) of oncology targets including transcription factors, directly comparable to Flare's heterobifunctional degrader approach embodied in FX-111.

TypeEmerging player
Description

Clinical-stage oncology company developing small molecule drugs targeting chromatin/epigenetic regulators, with comparable profile to Flare as a venture-backed precision oncology peer (and notable personal overlap given Flare President/CFO's prior role there).

6Inzen Therapeutics
TypeEmerging player
Description

Emerging oncology company founded by former Foghorn scientists targeting transcription factors and cell-state biology, representing an early-stage niche peer in the same switch-site-inspired drug discovery space.

TypeDirect peer
Description

Pioneer in targeted protein degradation (PROTAC) with oncology programs including ARV-110 for AR-driven prostate cancer, directly overlapping with Flare's FX-111 ARON program and its broader platform approach to previously undruggable targets.

TypeDirect peer
Description

Clinical-stage precision oncology company using motion-based drug design to target previously undruggable drivers including transcription-factor and chromatin regulators, with PI3K-alpha franchise comparable to Flare's biomarker-defined oncology strategy.

TypeBroad incumbent
Description

Commercial-stage precision oncology company targeting genomically defined patient populations with kinase inhibitors, operating a broader platform while sharing Flare's biomarker-driven patient selection and small molecule oncology approach.

TypeEmerging player
Description

Emerging clinical-stage company using AI-driven drug design to target transcription factors and other challenging protein classes in oncology, representing a niche but directly comparable approach to drugging transcription factors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Flare Therapeutics

Precision Oncology Therapeuticsflaretx.com

Flare Therapeutics is a clinical-stage biotechnology company developing precision oncology drugs by targeting transcription factors via its proprietary switch-site drug discovery platform. Its lead candidate FX-909 is in Phase 1B for biomarker-defined advanced urothelial cancer.

What Flare Therapeutics does

Flare's business model is currently pre-revenue and built on three pillars: (1) equity-financed internal drug development, with $82M raised in Series A (May 2021) and $123M in Series B (March 2023), totaling $205M in venture capital from investors including Third Rock Ventures, GordonMD Global Investments LP, Pfizer Ventures, Eli Lilly, Novartis, and Memorial Sloan Kettering Cancer Center; (2) strategic discovery and licensing collaborations, most notably the November 2024 Roche agreement providing $70M upfront plus potential milestones exceeding $1.8B and royalties, with Flare retaining ownership of its existing pipeline; and (3) clinical-trial collaborations, including a Merck supply agreement to evaluate FX-909 with KEYTRUDA. Future revenue is expected to come from drug commercialization (FX-909 targeting ~14,000 US cases of PPARG-high advanced urothelial cancer per year, within an 83,000+ US annual bladder cancer incidence), licensing royalties, and milestone payments. Distribution is conducted through approximately 12-15 US clinical trial sites under standard Phase 1B protocols. Leadership includes CEO Douglas Manion (appointed April 2024, formerly of Arena, Aclaris, BMS, GSK), CSO/Co-founder Robert Sims (ex-Constellation Pharmaceuticals), President/CFO Daphne Karydas, and CDO Michaela Bowden.

Flare Therapeutics firmographics

Firmographics
Name
Flare Therapeutics
Legal name
Flare Therapeutics Inc.
Website
https://flaretx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Flare Therapeutics is a clinical-stage biotechnology company developing precision oncology drugs by targeting transcription factors via its proprietary switch-site drug discovery platform. Its lead candidate FX-909 is in Phase 1B for biomarker-defined advanced urothelial cancer.
Ownership category
akta.pro rank

Flare Therapeutics industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Precision oncology therapeutics
  • Transcription factor drug discovery
  • Small molecule cancer drugs
  • Clinical-stage biotechnology
  • Urothelial cancer treatment

Where Flare Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Flare Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: Clinical-stage biotech with lead program FX-909 in Phase 1B. Revenue will come from drug sales upon regulatory approval. Partnered with Roche for discovery collaboration receiving $70M upfront with potential milestones exceeding $1.8B and royalties.
  2. Partnership and Collaboration Revenue: Strategic discovery collaboration with Roche worth up to $1.8B+ in milestones plus royalties. Retains co-funding option for one target for increased US royalties.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels4 records

Flare Therapeutics product offering

Product offering

Core offering

Flare Therapeutics is a clinical-stage biotechnology company developing precision oncology small-molecule drugs that target transcription factors using its proprietary "switch-site" drug discovery platform. Its lead asset FX-909 is an orally bioavailable PPARG inhibitor currently in Phase 1B clinical trials for biomarker-defined advanced urothelial cancer, and its second program FX-111 is a heterobifunctional degrader of ARON in IND-enabling studies for metastatic castration-resistant prostate cancer.

Product overview

Flare Therapeutics is a clinical-stage biotechnology company with a proprietary switch-site drug discovery platform focused on targeting transcription factors for precision oncology. The platform has identified more than 150 switch sites across transcription factor families. The company has two lead drug candidates: FX-909 (Phase 1B for urothelial cancer) and FX-111 (IND-enabling stage for prostate cancer), along with a discovery-stage portfolio targeting transcription factors in oncology and other therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • FX-909 First-in-class orally bioavailable small molecule inhibitor of PPARG (peroxisome proliferator-activated receptor gamma), a master regulator of the luminal lineage. Currently in Phase 1B clinical trial for locally advanced or metastatic urothelial cancer in biomarker-defined PPARG-high patient population.
  • FX-111 First-in-class heterobifunctional degrader of ARON (transcriptionally active, hormone-bound conformation of the androgen receptor). Currently in IND-enabling studies for treatment of metastatic castration-resistant prostate cancer (mCRPC).

Quantifiable outcome

  • Tumor regressions in 18 of 25 biomarker-defined patients (72%) including 5 confirmed partial responses and 1 complete response in Phase 1A study
  • +3 more outcomes

Companies that use Flare Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Flare Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Flare Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Merck (KEYTRUDA/pembrolizumab)coreStrategic or Co-development Partner · 21 October 2025Clinical trial collaboration and supply agreement to evaluate FX-909 in combination with KEYTRUDA (pembrolizumab) in new cohort of ongoing Phase 1 trial in metastatic urothelial cancer. Addresses potential to combine PPARG inhibition with anti-PD1 to overcome immune resistance.
  • RochecoreStrategic or Co-development Partner · 12 November 2024Strategic discovery collaboration leveraging Flare's proteomic and mass spectrometry platform to discover novel small molecule drugs targeting previously undrugged transcription factor targets in oncology. Flare receives $70M upfront and potential milestones exceeding $1.8B plus royalties. Flare retains co-funding option for one target for increased US royalties and retains ownership of existing pipeline.
  • PathAIminorStrategic or Co-development Partner · 4 October 2023Partnership to develop AI-based model that identifies luminal subtype urothelial cancer characterized by high PPARG expression using H&E-stained slides. Model achieved AUROC ≥95% accuracy across test, validation and independent datasets.
  • Caris Life SciencescoreStrategic or Co-development Partner · 13 April 2023Multi-year strategic preferred portfolio partnership providing comprehensive molecular profiling (whole exome and whole transcriptome sequencing) for patients in Flare's clinical trials. Leverages Caris' clinico-genomic database and AI/ML capabilities for biomarker-driven patient selection. Caris receives first option to develop companion diagnostic for any drug candidate from collaboration.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Flare Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Revolution Medicines: Clinical-stage precision oncology company developing inhibitors of difficult-to-drug oncogenic drivers (RAS, SHP2) with biomarker-defined patient strategies similar to Flare's PPARG-high urothelial approach.
  • Blueprint Medicines: Commercial-stage precision oncology company targeting genomically defined patient populations with kinase inhibitors, operating a broader platform while sharing Flare's biomarker-driven patient selection and small molecule oncology approach.

Direct peers

  • Kymera Therapeutics: Clinical-stage biotech using targeted protein degradation (Pegasus platform) to address transcription factors and other previously undruggable targets in oncology and immunology, with comparable platform-based pipeline strategy.
  • Foghorn Therapeutics: Clinical-stage biotech developing small molecule drugs against transcription factors and chromatin regulatory complexes for oncology, using a related 'gene traffic control' platform approach. Directly comparable as a transcription factor-targeting peer in precision oncology.
  • C4 Therapeutics: Clinical-stage biotech developing small molecule degraders (TORPEDO platform) of oncology targets including transcription factors, directly comparable to Flare's heterobifunctional degrader approach embodied in FX-111.
  • Arvinas: Pioneer in targeted protein degradation (PROTAC) with oncology programs including ARV-110 for AR-driven prostate cancer, directly overlapping with Flare's FX-111 ARON program and its broader platform approach to previously undruggable targets.
  • Relay Therapeutics: Clinical-stage precision oncology company using motion-based drug design to target previously undruggable drivers including transcription-factor and chromatin regulators, with PI3K-alpha franchise comparable to Flare's biomarker-defined oncology strategy.

Emerging players

  • Syndax Pharmaceuticals: Clinical-stage oncology company developing small molecule drugs targeting chromatin/epigenetic regulators, with comparable profile to Flare as a venture-backed precision oncology peer (and notable personal overlap given Flare President/CFO's prior role there).
  • Inzen Therapeutics: Emerging oncology company founded by former Foghorn scientists targeting transcription factors and cell-state biology, representing an early-stage niche peer in the same switch-site-inspired drug discovery space.
  • Accutar Biotech: Emerging clinical-stage company using AI-driven drug design to target transcription factors and other challenging protein classes in oncology, representing a niche but directly comparable approach to drugging transcription factors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Flare Therapeutics social profiles

Digital presence

Flare Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Flare Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Flare Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Flare Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flare Therapeutics

What does Flare Therapeutics do?

Flare Therapeutics is a clinical-stage biotechnology company developing precision oncology small-molecule drugs that target transcription factors using its proprietary "switch-site" drug discovery platform. Its lead asset FX-909 is an orally bioavailable PPARG inhibitor currently in Phase 1B clinical trials for biomarker-defined advanced urothelial cancer, and its second program FX-111 is a heterobifunctional degrader of ARON in IND-enabling studies for metastatic castration-resistant prostate cancer.

Is Flare Therapeutics a public or private company?

Flare Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Flare Therapeutics founded?

Flare Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Flare Therapeutics based?

Flare Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Flare Therapeutics make money?

Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are partnership and Collaboration Revenue.

Who are Flare Therapeutics's main competitors?

Broad incumbents on record are Revolution Medicines and Blueprint Medicines. Direct peers are Kymera Therapeutics, Foghorn Therapeutics, C4 Therapeutics, Arvinas and Relay Therapeutics. Emerging players are Syndax Pharmaceuticals, Inzen Therapeutics and Accutar Biotech.

Does Flare Therapeutics have an API?

No public API is recorded for Flare Therapeutics.

What industry is Flare Therapeutics in?

Flare Therapeutics's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceFlare Therapeutics Appoints Peter Lebowitz, MD, PhD, to Board of Directors and Brian DeSchuytner as Chief Financial Officer and Chief Business OfficerFlare Therapeutics appointed Peter Lebowitz to its board and Brian DeSchuytner as CFO and CBO. Lebowitz brings oncology drug development expertise, while DeSchuytner brings finance and business strategy experience. The appointments aim to support advancing the company's AR(ON)-targeting prostate cancer programs.Phirda融资21亿元:礼来为何押注这家核药公司?In July, biotech financing totaled $166.5M across 15 deals, with nuclear medicine and AI drug discovery leading. LEO Pharma backed AdvanCell's $315M D-round, expanding its partnership for alpha-particle therapies. Other notable rounds included Chai Discovery's $400M C-round and Celea's $100M funding.VC News DailyFlare Therapeutics Secures $85M Series C RoundFlare Therapeutics Inc., a clinical-stage biotechnology company based in Cambridge, Massachusetts, announced the closing of an $85 million Series C financing round led by Third Rock Ventures and Nextech Invest, with participation from multiple investors including Pfizer Ventures, Eli Lilly and Company, and Novartis. The company also announced the appointment of Anna Protopapas as Chief Executive Officer concurrent with the financing. Proceeds will be used to advance the company's prioritized programs and for working capital and general corporate purposes.pharmaphorumRespiratory biotech Celea raises $180m, and other financingsPureTech Health's subsidiary Celea Therapeutics raised $180 million in financing to advance its deuterated pirfenidone derivative (deupirfenidone/LYT-100) into phase 3 trials for idiopathic pulmonary fibrosis, with the round co-led by RA Capital Management and Leaps by Bayer. This week's biotech financing roundup also includes Beeline Medicines' $126 million Series A extension, Flare Therapeutics' $85 million Series C with new CEO Anna Protopapas, Lycia Therapeutics' $75 million Series D, and Telum Therapeutics' €18 million Series A for antimicrobial development.TechStartupsVenture Capital & Startup Funding Roundup, July 1, 2026A July 2026 startup funding roundup reveals over $1.4 billion in venture capital deployed across ten companies, with the largest checks directed at AI infrastructure and specialized hardware rather than consumer applications; Together AI led the pack with an $800 million Series C at an $8.3 billion valuation, followed by biotech companies Beeline Medicine ($126.3 million) and Flare Therapeutics ($85 million), and defense tech firm Dominion Dynamics ($100 million). The funding pattern indicates investors are prioritizing the "plumbing" of AI deployment—including data-center reliability, chip architecture, and precision timing—alongside biotech with clear clinical milestones, reflecting a shift from speculative AI ventures toward solutions addressing practical bottlenecks and mission-critical problems.TechStartupsVenture Capital & Startup Funding Roundup, June 30, 2026A June 30, 2026 venture funding roundup documented 10 startup funding rounds totaling approximately $618 million, with the largest going to LeapXpert ($180M for governed enterprise communications), Beeline Medicines ($126.3M Series A extension for autoimmune drug development), Higharc ($95M for AI-powered homebuilding software), and Flare Therapeutics ($85M Series C for prostate cancer program). The report indicates investors are shifting capital away from foundation AI models toward infrastructure, software, and specialized hardware that serve regulated enterprise workflows, semiconductor timing, construction operations, and biotech with visible clinical milestones, with four deals accounting for nearly 80% of disclosed capital.GlobeNewswireFlare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive OfficerFlare Therapeutics Inc. closed an $85 million Series C financing round led by existing investors Third Rock Ventures and Nextech Invest, with participation from Pfizer Ventures, Eli Lilly and Company, Novartis, and others. The company appointed veteran biotech executive Anna Protopapas as Chief Executive Officer to guide its next phase of growth focused on prostate cancer. Proceeds will fund advancement of FX-111, a first-in-class AR ON degrader targeting prostate cancer, to proof-of-concept and preclinical development of the AR ON RIPTAC program.Venture Capital Access OnlineFlare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive OfficerFlare Therapeutics closed an $85 million Series C financing led by Third Rock Ventures and Nextech Invest, appointing Anna Protopapas as CEO. Proceeds will advance FX-111, an ARON degrader for prostate cancer, with FDA IND clearance and expected Phase 1A in Q3 2026.BioWorldFX-111 targets persistent androgen signaling in prostate cancerResearchers from Flare Therapeutics presented the preclinical profile of FX-111, a selective active androgen receptor degrader, in prostate cancer models. The presentation was given at the American Association for Cancer Research meeting.GlobeNewswireFlare Therapeutics Announces Three Upcoming Poster Presentations at AACR Annual Meeting 2026Flare Therapeutics announced three poster presentations at the AACR Annual Meeting 2026 in San Diego, covering its lead programs FX-909 and FX-111. FX-909, a PPARG inhibitor for urothelial cancer, showed on-target activity and immune modulation in a Phase 0 study. FX-111, a degrader for AR ON, is in IND-enabling studies for prostate cancer.